Inside Precision Medicine December 8, 2023
Researchers at Case Western Reserve University say that a class of diabetes drugs used to treat type 2 diabetes may reduce the risk of the development of colorectal cancer (CRC). The drugs, called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs are medications that are given by injection to lower blood sugars, improve insulin sensitivity, and can help manage weight. This class of drugs has also recently taken off as a weight loss medication.
Results of the study were published this week in the journal JAMA Oncology.
“Our results clearly demonstrate that GLP-1 RAs are significantly more effective than popular anti-diabetic drugs, such as Metformin or insulin, at preventing the development of CRC,” said co-lead researcher Nathan Berger, a professor at...